TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the third quarter ended September 30, 2025 (“Q3 2025”) and provided a corporate update on recent achievements and upcoming milestones.
The Company’s unaudited condensed interim consolidated financial statements for the nine months ended September 30, 2025, and accompanying management’s discussion and analysis, can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.